



ASX Announcement | 20 March 2026  
**AdAlta Limited (ASX:1AD)**

**Canadian patent protecting AD-214 granted**

Grant completes composition of matter protection for AD-214 in major markets

**Investment highlights**

- Patent protecting AD-214 granted by Canadian Intellectual Property Office
- AD-214 now protected by composition of matter patents in all major commercial markets

**AdAlta Limited (ASX:1AD)** (“AdAlta” or “the Company”), developer of next generation cell and protein therapeutic products is pleased to announce that it has been granted a new composition of matter patent relating to its first in class anti-fibrotic product, AD-214, by the Canadian Intellectual Property Office.

Canadian Patent Number 2,973,317, entitled “CXCR4 binding molecules”, has an expiry date of 8 January 2036.

**AdAlta CEO and Managing Director, Tim Oldham said:** “*Composition of matter patents are the strongest form of patent protection and a key part of the data package partners expect from us. This Canadian patent completes the protection of AD-214 in all major commercial markets and its potential supply chain.*”

The new patent protects the i-body® sequence used in AdAlta’s lead product, AD-214, sequences similar to this, and pharmaceutical compositions and derivatives containing these i-body® sequences. The patent also protects the use of these sequences in therapeutic and diagnostic applications, including Idiopathic Pulmonary Fibrosis (IPF) and kidney fibrosis, the primary indications for which AD-214 is being developed.

Patents are granted on a country-by-country basis, and AD-214 is now protected in its likely major commercial markets (US, Canada, European Union and Japan) as well as key potential manufacturing locations (India and China) and several other markets until 2036. AdAlta has also made applications for patents related to dosing and methods of treatment that, if granted, would provide additional protection until 2043.

To view a summary and engage in discussion about this announcement visit AdAlta’s InvestorHub here: <https://investorhub.adalta.com.au/link/e9Q82e>

This ASX announcement has been authorised for release by the Board of AdAlta Limited (ASX:1AD).

**For further information, please contact:**

**AdAlta Limited (ASX:1AD)**  
Tim Oldham  
CEO & Managing Director  
P: +61 403 446 665  
E: [ir@adalta.com.au](mailto:ir@adalta.com.au)

**About AdAlta**

For personal use only

AdAlta (ASX: 1AD) is a clinical stage biotechnology business addressing the need for effective cellular immunotherapies for the treatment of solid cancers.

Through its subsidiary company, AdCella Pty Ltd's 'East to West' strategy, the Company is integrating Asia's prowess in T cell therapy development with the efficiency and quality of Australia's clinical and manufacturing ecosystem to create a pathway connecting 'Eastern' innovation in cellular immunotherapies with 'Western' regulated markets and patients.

AdCella in-licenses products from Asian originators and invests to establish US FDA regulated manufacturing and conduct Phase I clinical studies with potential to position each product for on-licensing to larger biopharmaceutical companies for potential registrational studies and commercialization.

AdCella implements a disciplined approach to asset selection focused on highly differentiated T cell therapy products supported by clinical data in solid cancers. The company adopts a capital efficient business model delivering a rapid return on investment in each project that is replicable and provides opportunities to scale across multiple products.

Solid tumours account for 90% of cancers yet remain underserved by current cellular immunotherapies. AdCella aims to dominate this high-growth segment. The cellular immunotherapy market is projected to grow at a compound annual growth rate of 34% to reach US\$20.3 billion by 2028.

AdCella's first asset, BZDS1901, is a first in class CAR-T cell therapy for mesothelioma and other solid cancers including lung and gynaecological cancers. BZDS1901 is the first CAR-T product for mesothelioma to secrete its own immune checkpoint inhibitor "armouring" to help overcome tumour immune suppression, is manufactured in less than two days without expensive viral vectors, and has demonstrated clinical potential, including difficult to achieve complete responses in advanced mesothelioma in China.

Separately, AdAlta's first in class fusion protein, AD-214, takes a whole new approach to fibrotic diseases of the lung and kidney, such as the degenerative and fatal Idiopathic Pulmonary Fibrosis. Following demonstration of efficacy in multiple animal models of disease and two successful Phase I clinical studies, AD-214 is available for partnering. AdAlta's first in class i-body®, WD-34, is a discovery stage asset being advanced through partnering as a potentially transformational prophylaxis and treatment for malaria.

To learn more, please visit: [www.adalta.com.au](http://www.adalta.com.au)

#### For more information



Join our [InvestorHub](#)



Follow us on [LinkedIn](#)



Follow us on [X \(formerly Twitter\)](#)